Navigation Links
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Date:8/28/2008

OSLO, August 28 /PRNewswire-FirstCall/ --

- Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC)

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Pain palliation is an important quality of life benefit in metastatic cancer patients. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, no significant bone marrow toxicity was observed.

In men with HRPC life expectancy can be as short as 18 months, and it is estimated that 100,000 men in the EU and USA die from the disease each year. In 85% of these men the tumor will have spread into the bones. These metastases are a significant problem as they can cause intractable and debilitating pain as well as contributing to a further reduction in life expectancy.

The BC1-03 study was a double-blind randomised pain control study comparing the palliative effects of four different single dose levels of Alpharadin in patients with bony metastatic HRPC. The drug was given by i.v. injection mainly on an outpatient basis. The palliative efficacy of Alpharadin was measured using an assessment of bone pain as well as the patient's consumption of analgesia. The primary study objective was to investigate whether there was a dose-response relationship with respect to pain palliation in this patient group. The study has shown the beneficial palliative effect of a single dose of Alpharadin and that there is a clear dose-response effect, with higher doses providing better pain relief.

The study also showed a dose-dependent reduction in bone al
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Misonix, Inc. (NASDAQ: MSON ), an international ... innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and ... financial results for the first quarter fiscal year 2015 ... a conference call that same day, Thursday, November 6, ... Interested parties can access the conference ...
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  Electronic health records ... a result of government initiatives and the considerable ... providers have invested over the past five years. ... health IT, and U.S. clinicians use them on ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Aug. 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a ... six-months ended June 30, 2011. Key Recent ... of data from the open-label phase 2 study of Arikace™ ... (CF) patients with Pseudomonas lung infections ...
... (NYSE Amex: ANX ) today reported financial results ... we head into the second half of the year, we ... into the U.S. market, should it be approved on or ... Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Having a ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8ADVENTRX Reports Second Quarter 2011 Financial Results 2ADVENTRX Reports Second Quarter 2011 Financial Results 3ADVENTRX Reports Second Quarter 2011 Financial Results 4ADVENTRX Reports Second Quarter 2011 Financial Results 5ADVENTRX Reports Second Quarter 2011 Financial Results 6ADVENTRX Reports Second Quarter 2011 Financial Results 7
(Date:10/31/2014)... terms of duration of treatment and cost, patients ... accelerated partial breast irradiation (APBI) with proton therapy ... research from The University of Texas MD Anderson ... cost analysis study based on typical patient characteristics, ... charges for eight different types of partial and ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... scientists have found a drug combination that can trigger ... the way for new treatments, according to research that ... (NCRI) Cancer Conference in Liverpool next week*. , When ... chain of events culminating in self destruction. But cancer ... immortal. This means that cells grow out of control ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
(Date:10/31/2014)... Radiology and EMR Integration , “Surveys ... diagnostic imaging centers but Connectivity is Opportunity,” says ... “Differentiation is critical in all businesses today and ... the intense competition and the downward pressure on ... from the competition by fully integrating with the ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc., ... "Company"),(which recently changed its name from Genesis ... U.S. pharmaceutical company with its,principal operations in ... today,that its management will present at the ...
... Online Resource, YouCanBeTheOne.com, Recommended to Help Guide Important Conversations ... YORK, May 12 The multi-disciplinary expert consortium known ... calling upon family and friends to proactively start a ... physician at the first sign of possible Alzheimer,s disease ...
... Commissioned by Non-Profit Identifies Unmet Needs of CaregiversWASHINGTON, May ... Wellness Community revealed many Americans who provide support to ... as a caregiver. In fact, only 20 percent ... estimate of 60 percent. This year, it is projected ...
... and Pharma on PanelWALTHAM, Mass., May 12 ... ) announced today that CEO Lewis H. Bender will ... Markers in Drug Development: How Personalized Medicine is Evolving ... May 18-21, 2009 in Atlanta, GA. The panel ...
... DOYLESTOWN, Pa., May 12 The Quigley Corporation (Nasdaq: ... today announced that the world,s leading independent proxy advisory ... Glass Lewis & Co. have recommended that stockholders vote ... investor Ted Karkus, solicitation seeking control of the Board ...
Cached Medicine News:Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 2Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 5Health News:Cancer Caregiver Distress Unrecognized and Under Reported 2Health News:Cancer Caregiver Distress Unrecognized and Under Reported 3Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 2Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 2Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 4
3.5 mm blade. Round handle. Designated most popular model or size....
7 mm curved blade. Round handle....
1.5 mm long blade. Square handle....
Double-ended. 0.9 mm x 1 mm blade. Angled at 90 and 120 degrees. Round handle. Designated most popular model or size....
Medicine Products: